This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

Vestal Point Capital sold 1,054,000 Nuvalent shares in Q4, an estimated $103.93M based on the quarter’s average price; the fund’s quarter-end Nuvalent position declined by $90.50M and it now holds 46,000 shares valued at $4.63M. The sale reduced Nuvalent to under 1% of the fund's 13F AUM; Nuvalent closed at $102.24 on 2/17/26 (up 29.11% Y/Y) with a $7.43B market cap and TTM net loss of $425.4M. Company cash was reported at roughly $1.4B at end-2025 (runway into 2029), and upcoming regulatory catalysts include a potential FDA action in September for zidesamtinib and a planned neladalkib filing.

Analysis

A large institutional trim in a small-to-mid cap clinical biotech often does more to change the stock’s microstructure than it signals binary clinical probability. The immediate effect is higher intraday supply and a lower institutional stake concentration, which increases the sensitivity of the share price to single-event liquidity (earnings, readouts, partnership rumors) and makes any future buying rounds more impactful per dollar deployed.

For competitors and later-stage partners, a re-priced focal biotech creates windows for acquisition or licensing arbitrage: an approving decision would quickly re-rate the space and force peers to reprice peak-sales assumptions, while a setback will shift M&A appetite toward assets with clearer CNS penetration or differentiated resistance profiles. Payor and label scope second-order effects matter here — a broad CNS label expands addressable market multiplicatively, while a narrow label makes the asset attractive primarily to specialty buyers.

Primary risks are classic binary biotech ones: regulatory denial, safety signals, or a need to raise capital at a lower valuation that dilutes existing holders. Timing mismatch between market sentiment (short-term momentum) and the multi‑quarter clinical/regulatory timeline can produce mispriced implied volatility; that gap is where option structures can buy asymmetric exposure without owning full equity risk.

Contrarian read: the block sale is equally consistent with tactical portfolio rebalancing as it is with loss of confidence — the right reading is position-contextual, not headline-driven. Given the company’s runway to execute multiple milestones, patient, structured exposure (defined-cost option spreads or small-sized equity with hedges) offers the cleanest asymmetric payoff versus naked long/short bets presuming volatility compresses post-catalyst.

Key Decisions for Investors

• Small asymmetric long: Buy 18–24 month NUVL LEAP calls sized 1–2% of fund NAV (or a 2x/3x notional exposure if options) and hedge with a 30–40% OTM protective put or a short biotech ETF (XBI) position sized to neutralize sector beta. R/R: asymmetric upside (3x+ if positive regulatory outcome or partnership) vs defined option premium loss.
• Catalyst call spread: Enter a 6–9 month NUVL call debit spread (buy near-the-money, sell 25–40% OTM) sized 0.5–1% NAV to cap premium while retaining upside into the next regulatory/readout window. R/R: limited downside (premium) and 2–4x capped upside if the market re-rates.
• Pair hedge: Long NUVL equity (1% NAV) paired with a 0.5x short position in a large-cap biotech (e.g., BMRN) to isolate idiosyncratic binary risk and reduce sector beta. R/R: retains asymmetric idiosyncratic upside while limiting sector drawdowns during a negative biotech tape.